Tesamorelin: FDA-Approved Growth Hormone Peptide

Tesamorelin occupies a unique position in the peptide landscape. It is one of the very few peptides with full FDA approval, giving it a level of clinical validation that most compounds in the optimization medicine space simply do not have. With over 53,000 monthly searches, it is also one of the most sought-after peptides by people looking to address body composition, visceral fat accumulation, and the broader effects of growth hormone optimization.

This guide covers how tesamorelin works, what the clinical evidence actually shows, how it compares to other growth hormone secretagogues, and what you need to understand before considering it. We do not provide dosing information. Tesamorelin therapy should only be pursued under the guidance of a licensed physician who can evaluate your individual situation, prescribe appropriately, and monitor your response.

What is tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal produced by the hypothalamus that tells the pituitary gland to manufacture and release growth hormone. Marketed under the brand name Egrifta, tesamorelin received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a metabolic complication of antiretroviral therapy that causes abnormal fat distribution.

The peptide consists of 44 amino acids, making it identical in length to the active fragment of natural human GHRH with one critical modification: a trans-3-hexenoic acid group attached to the tyrosine at position one. This chemical modification is not cosmetic. It significantly increases the peptide's biological potency and extends its duration of action compared to unmodified GHRH. The result is a compound that stimulates growth hormone release more effectively than the body's own signaling molecule.

What makes tesamorelin fundamentally different from exogenous growth hormone therapy is the mechanism of action. Exogenous growth hormone, such as somatropin, introduces synthetic growth hormone directly into the bloodstream. This bypasses the body's regulatory feedback systems, which can lead to supraphysiological hormone levels and a range of side effects. Tesamorelin instead works upstream, stimulating the pituitary gland to produce its own growth hormone through the normal secretory pathway. This preserves the pulsatile release pattern that characterizes natural growth hormone secretion, and the body's feedback mechanisms remain intact to prevent excessive hormone levels.

This distinction between stimulating natural production and introducing exogenous hormone is central to understanding why GHRH analogs like tesamorelin and sermorelin are favored by many optimization medicine physicians over direct growth hormone replacement. The physiological approach tends to produce a more moderate, sustainable elevation in growth hormone and IGF-1 levels with a lower risk of the side effects associated with supraphysiological growth hormone exposure.

How tesamorelin works

Tesamorelin's mechanism is straightforward in concept but elegant in execution. When administered, the peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. These are the same receptors that respond to the body's endogenous GHRH, but tesamorelin activates them with greater potency due to its structural modification.

Pituitary stimulation.Upon binding, tesamorelin triggers the somatotroph cells to synthesize and release growth hormone into the bloodstream. This release follows the natural pulsatile pattern rather than creating a constant elevated level, which is important because many of growth hormone's biological effects are mediated by the pulse amplitude and frequency rather than by absolute levels. The pulsatile pattern also allows growth hormone receptors throughout the body to maintain their sensitivity, whereas constant exposure can lead to receptor downregulation.

IGF-1 production.The growth hormone released in response to tesamorelin travels to the liver and other tissues, where it stimulates the production of insulin-like growth factor 1 (IGF-1). IGF-1 is the primary mediator of many of growth hormone's anabolic and metabolic effects, including its impact on body composition, tissue repair, and cellular metabolism. The increase in IGF-1 from tesamorelin therapy is generally moderate and within physiological ranges, which differentiates it from exogenous growth hormone therapy that can push IGF-1 to supraphysiological levels.

Lipolysis activation.Growth hormone is one of the most potent lipolytic hormones in the body, meaning it promotes the breakdown of stored fat for energy. This effect is particularly pronounced in visceral adipose tissue, the metabolically active fat that accumulates around internal organs and is associated with cardiovascular disease, insulin resistance, and systemic inflammation. Tesamorelin's ability to preferentially reduce visceral fat is the basis for its FDA-approved indication and one of its most clinically significant effects.

Feedback preservation.Because tesamorelin works through the natural GHRH pathway rather than introducing exogenous growth hormone, the body's negative feedback systems remain functional. Somatostatin, the hormone that counterbalances GHRH and inhibits growth hormone release, continues to operate normally. This built-in safety mechanism helps prevent growth hormone levels from rising to dangerous levels, a risk that is more significant with direct growth hormone administration.

Clinical evidence

Tesamorelin benefits from something rare in the peptide world: robust clinical trial data from the studies that supported its FDA approval. This evidence base is substantially stronger than what exists for most other peptides used in optimization medicine.

Visceral fat reduction

The pivotal clinical trials for tesamorelin demonstrated significant and clinically meaningful reductions in visceral adipose tissue. In two Phase III randomized, double-blind, placebo-controlled trials involving over 800 HIV-positive patients with abdominal lipodystrophy, tesamorelin produced an average reduction in trunk fat of approximately 15 to 18 percent over 26 weeks of treatment. This reduction was measured by CT scan, which provides precise quantification of visceral fat that is not possible with simple waist measurements or body weight.

The visceral fat reduction was accompanied by improvements in body image perception and patient-reported outcomes related to abdominal distension and appearance. Importantly, the fat reduction was specific to the visceral compartment. Subcutaneous fat and limb fat, which are already depleted in many HIV patients with lipodystrophy, were not significantly affected. This selectivity is meaningful because indiscriminate fat loss could worsen the already abnormal fat distribution in these patients.

Extension studies showed that the visceral fat reduction was maintained with continued treatment but reversed upon discontinuation, indicating that tesamorelin addresses the metabolic drivers of visceral fat accumulation rather than permanently altering fat cell biology. This is consistent with the mechanism of action: the growth hormone stimulation that drives lipolysis ceases when the drug is stopped.

Metabolic effects

Beyond fat reduction, clinical trials revealed several metabolic effects. Tesamorelin treatment was associated with improvements in triglyceride levels, with treated patients showing meaningful reductions compared to placebo. Total cholesterol and non-HDL cholesterol also trended toward improvement. These lipid effects are consistent with the known metabolic actions of growth hormone and the reduction in metabolically active visceral fat.

The relationship between tesamorelin and glucose metabolism is more nuanced. Growth hormone has counter-regulatory effects on insulin, meaning it tends to increase blood glucose and reduce insulin sensitivity. Clinical trial data showed modest increases in fasting glucose and HbA1c in some tesamorelin-treated patients, though these changes were generally small and clinically manageable. This effect is one of the reasons physician monitoring of glucose and insulin markers is important during tesamorelin therapy.

Off-label body composition use

The use of tesamorelin for body composition optimization in non-HIV patients is based on extrapolation from its FDA-approved indication and the well-established effects of growth hormone on fat metabolism. While formal clinical trials in this population are limited, the mechanism of action, stimulating endogenous growth hormone to promote visceral fat lipolysis, is not specific to HIV-associated lipodystrophy. The growth hormone pathway operates the same way regardless of the underlying cause of visceral fat accumulation.

Many optimization medicine physicians prescribe tesamorelin off-label for patients with elevated visceral fat, age-related changes in body composition, or as part of broader metabolic optimization protocols. Off-label prescribing is a common and legal practice in medicine, provided the physician has a reasonable clinical basis for the prescription and the patient is appropriately informed and monitored.

Tesamorelin vs. other GHRH analogs

The growth hormone secretagogue landscape includes several compounds, and understanding how tesamorelin compares to alternatives is important for making informed decisions. The most relevant comparisons are with sermorelin and the CJC-1295/Ipamorelin combination.

Tesamorelin vs. sermorelin. Both are GHRH analogs that stimulate natural growth hormone production. Sermorelin is a 29-amino-acid peptide corresponding to the first 29 amino acids of natural GHRH, while tesamorelin is a 44-amino-acid modified version with enhanced potency. Tesamorelin has the advantage of FDA approval and robust clinical trial data. Sermorelin, while lacking current FDA approval, has a long history of clinical use and is widely available through compounding pharmacies as a Category 1 peptide. Some practitioners consider tesamorelin the more potent option, particularly for visceral fat reduction, while sermorelin may be preferred for patients seeking a gentler approach to growth hormone optimization.

Tesamorelin vs. CJC-1295/Ipamorelin.The CJC-1295/Ipamorelin combination works through both the GHRH pathway (CJC-1295) and the ghrelin/growth hormone secretagogue receptor pathway (Ipamorelin), providing dual-mechanism stimulation of growth hormone release. This combination may produce a stronger overall growth hormone response than tesamorelin alone, but it lacks the FDA approval and clinical trial rigor that tesamorelin has. The choice between these options often comes down to the specific clinical goals, the patient's response profile, and physician preference.

Legal status

Tesamorelin holds Category 1 status, making it fully legal for prescription and compounding in the United States. This is the most favorable regulatory classification for a peptide, and it reflects the compound's FDA approval and established safety profile.

There are two pathways for accessing tesamorelin. The branded version, Egrifta, is available through traditional pharmacies with a prescription. Compounded formulations are available through licensed 503A and 503B compounding pharmacies, also with a valid prescription. The compounded versions are generally more accessible and more affordable than the branded product, which is one reason they have become the preferred option for off-label body composition use.

Because tesamorelin is Category 1, it did not face the regulatory disruptions that affected Category 2 peptides during the 2024-2025 enforcement actions. Patients and physicians can access it through standard legal channels without the uncertainty that surrounds compounds like BPC-157 or TB-500 that are pending reclassification. For a complete understanding of the peptide legal framework, see our guide: Are Peptides Legal?.

Safety considerations

Tesamorelin's FDA approval means it has undergone the rigorous safety evaluation process required by the FDA, which includes extensive preclinical testing and multiple phases of human clinical trials. This provides a level of safety data that is simply not available for most other peptides in the optimization space.

The most commonly reported adverse effects in clinical trials include injection site reactions, arthralgia (joint pain), myalgia (muscle pain), peripheral edema (fluid retention), and pain in extremities. These effects are generally mild to moderate and are consistent with the known effects of increased growth hormone activity.

There are important contraindications. Tesamorelin should not be used in patients with active malignancy, as growth hormone can promote tumor growth. It is contraindicated in pregnancy. Patients with a history of hypersensitivity to tesamorelin or mannitol should not use it. The effect on glucose metabolism requires monitoring in patients with diabetes or prediabetes, and adjustments to diabetes medications may be necessary.

Physician supervision is not merely recommended for tesamorelin therapy; it is the standard of care. A qualified physician will evaluate your suitability for treatment, order appropriate baseline and monitoring labs including IGF-1, glucose, and HbA1c, screen for contraindications, and adjust therapy based on your response. For guidance on finding the right provider, see our guide on hormone optimization.

Frequently asked questions

What is tesamorelin used for?

Tesamorelin is FDA-approved for the treatment of HIV-associated lipodystrophy, a condition involving excess visceral fat accumulation in HIV-positive patients on antiretroviral therapy. Off-label, it is prescribed by physicians for body composition optimization, visceral fat reduction, and growth hormone stimulation in non-HIV patients. As a GHRH analog, it works by stimulating the pituitary gland to produce natural growth hormone rather than introducing exogenous growth hormone directly.

Is tesamorelin legal?

Yes. Tesamorelin is a Category 1 peptide with full FDA approval. It is available through both traditional pharmacies under the brand name Egrifta and through licensed compounding pharmacies. A valid prescription from a licensed physician is required. For a comprehensive overview of peptide legality, see Are Peptides Legal?.

How is tesamorelin different from sermorelin?

Both are growth hormone-releasing hormone analogs that stimulate natural growth hormone production. Tesamorelin is a 44-amino-acid peptide with a structural modification that increases its potency, and it has FDA approval. Sermorelin is a 29-amino-acid peptide without current FDA approval but with a long history of clinical use. Tesamorelin may produce a stronger growth hormone response, particularly for visceral fat reduction, while sermorelin is widely used as an accessible Category 1 option for general growth hormone optimization.

Does tesamorelin reduce belly fat?

In clinical trials, tesamorelin reduced visceral adipose tissue by approximately 15 to 18 percent over 26 weeks. This effect was specific to visceral fat, the metabolically active fat around internal organs, rather than subcutaneous fat. The reduction was maintained with continued treatment but reversed upon discontinuation. Off-label use for body composition in non-HIV patients is based on these clinical findings and the known effects of growth hormone on fat metabolism.

What are the side effects of tesamorelin?

The most commonly reported side effects include injection site reactions, joint pain, muscle pain, peripheral edema, and pain in extremities. Because tesamorelin increases growth hormone levels, it may cause fluid retention, carpal tunnel symptoms, and modest increases in blood glucose. It should not be used by individuals with active malignancy, as growth hormone can promote tumor growth. All therapy should be supervised by a physician who can monitor for adverse effects and screen for contraindications.